Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURF: Innovative Treatment of Urethral Stenosis With Autologous ADSVF
NCT05857371Phase 2Recruiting
- Sponsor
- Assistance Publique-Hôpitaux de Marseille
- Start
- Mar 2024
- Primary completion
- Nov 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of autologous adipose-derived stromal vascular fraction in Urethral stenosis (2 arms), sponsored by Assistance Publique-Hôpitaux de Marseille. Primary endpoints: Intensity and duration of urethral pain at 24 months, Incidence of urinary infection at 24 months and 2 more. Started Mar 2024; status: recruiting.
02
Drugs
autologous adipose-derived stromal vascular fraction
03
Conditions
Urethral stenosis
Beyond the preview
Go deeper on NCT05857371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857371.